

Bayer 10,159.3-HCL
Le 33 364#11
6/18/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : SCHOOP et al.
SERIAL NO. : 09/889,455
FILED : 9 January 2002
FOR : β -PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
ART UNIT : 1621
EXAMINER : Brian J. Davis

13 June 2003

Hon. Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION FOR SUSPENSION OF ACTION UNDER 37 CFR § 1.103(a)

SIR:

In conjunction with the applicants' filing of the Amendment filed under 37 CFR § 1.111, please accept this petition for a three (3) month suspension of action.

In accordance with the requirement under 37 CFR 1.103(a) to show good and sufficient cause for suspension of action, the undersigned states that this application serial number was recently transferred to the undersigned's firm and as such request is made on behalf of the applicants for a suspension of time so that the present application can be further reviewed for its relationship to prior application filings.

CONDITIONAL PETITION FOR EXTENSION OF TIME

If entry and consideration of the amendments above requires an extension of time, Applicants respectfully request that this be considered a petition therefor. The Assistant Commissioner is authorized to charge any fee(s) due in this connection (including 37 CFR § 1.17(h)) to Deposit Account No. 14-1263.

ADDITIONAL FEE

Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

Closing

A favorable decision on this petition is respectfully requested. If any further information is needed, please feel free to contact the undersigned at the telephone number below.

Respectfully submitted,

Norris, McLaughlin & Marcus, P.A.

By: Howard C. Lee
Howard C. Lee
Reg. No. 48,104

220 East 42nd Street
30th Floor
New York, New York 10017
(212) 808-0700

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that the foregoing Amendment under 37 CFR § 1.111 (2 pages total) is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below:

Date: 13 June 2003

By: Julie Harting
Julie Harting